Does Cosentyx (secukinumab) suppress the immune system?
Cosentyx (secukinumab) can change parts of your immune response, but it does not work as a broad “overall immune system suppressant” like some older immune-suppressing drugs. It targets a specific immune pathway by blocking interleukin-17A (IL-17A), a signaling protein involved in inflammation in conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Because it affects immune signaling, it can increase susceptibility to certain infections. [1]
What kinds of infections are patients warned about?
Blocking IL-17A is associated with higher risk of some infections, particularly those involving the skin or mucous membranes and candidiasis (thrush). If an infection occurs or symptoms suggest infection, clinicians may interrupt or delay treatment. [1]
How big is the infection risk compared with other biologics?
Within immune-targeting biologics, Cosentyx’s risk profile is generally tied to its specific IL-17A mechanism. In practice, infection risk depends on factors like other medications you take (especially systemic steroids or other immunosuppressants), your baseline health, and how active your underlying disease is. If you want a direct comparison to another biologic (for example, TNF inhibitors), that depends on your condition and medical history. [1]
Can you still get vaccines while on Cosentyx?
Because Cosentyx modulates immune signaling, many clinicians advise avoiding live vaccines while on biologic therapy. Inactivated vaccines may still be used, but timing and vaccine choice should be confirmed with your prescriber. [1]
What should you do if you think you’re getting an infection?
Contact your clinician promptly if you develop symptoms of infection (fever, worsening cough, sore throat, painful or worsening skin lesions, or signs of thrush). Your prescriber may assess whether to hold Cosentyx until the infection is under control. [1]
Who should use Cosentyx cautiously?
People with recurrent infections, chronic or serious infections, or specific infection risks (such as a history of recurrent thrush) typically need closer monitoring and individualized treatment decisions. [1]
Sources:
[1] U.S. Food and Drug Administration. Cosentyx (secukinumab) Prescribing Information (infection/candida warnings and mechanism). https://www.accessdata.fda.gov/